We, AnGes MG, are pleased to announce that our basic patent which widely covers HGF gene therapy has been granted in Europe (EP0847757B1).  This European patent is granted following our US and Japanese HGF patent.

Japan, US and Europe are leading pharmaceutical markets.  Therefore, now we have the exclusive right to undertake HGF gene therapy business in these major countries.

This European patent covers 18 countries, Austria, Belgium, Switzerland, Liechtenstein, Germany, Denmark, Spain, Finland, France, England, Greece, Ireland, Italy, Luxemburg, Monaco, Holland, Portugal and Sweden, so this patent will strongly assist our HGF gene therapy business in Europe.

The patent right includes all “the pharmaceuticals comprising HGF gene which are used for treatment of disease for which HGF is effective”.  This patent strongly and widely supports our HGF gene therapy clinical trial projects for various indications, not only peripheral arterial disease and ischemic heart disease for which we are currently developing but also other indications.

We are establishing a strong patent network for our international clinical development of HGF gene therapy.  Our HGF patents have also been granted in other countries:

Japanese Patent : No. 3431633
US Patent : No.6248722
Australian Patent : No.745887
New Zealand Patent : No.315769

Patent applications have been also filed in China, South Korea and Taiwan.
We have been filing a series of patent applications also for other diseases to further enhance the effect of this basic patent.  We will keep trying to improve and expand the use of HGF gene therapy.

We try to have our intellectual properties respected by other companies, and at the same time, we do respect other companies’ intellectual properties.